Holen Sie sich die Stockscreener-App
191.24
0.04%
-0.07
Handel nachbörslich:
191.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$191.31
Offen:
$192.97
24-Stunden-Volumen:
269.29K
Relative Volume:
1.20
Marktkapitalisierung:
$3.75B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
76.19
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
+0.67%
1M Leistung:
+5.66%
6M Leistung:
+74.82%
1J Leistung:
+73.79%
1-Tages-Spanne:
$183.91
$193.02
1-Wochen-Bereich:
$182.87
$194.44
52-Wochen-Spanne:
$93.58
$194.44
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
191.24 | 3.73B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
How supply chain issues affect Ligand Pharmaceuticals Incorporated stock2025 Short Interest & Accurate Technical Buy Alerts - newser.com
How Investors Are Reacting To Ligand Pharmaceuticals (LGND) Management's Engagement Surge and Analyst Optimism - Yahoo Finance
Oppenheimer Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Ligand Pharmaceuticals (LGND) to $250 | LGND Stock News - GuruFocus
Intraday pattern recognizer results for Ligand Pharmaceuticals IncorporatedQuarterly Profit Report & Weekly Market Pulse Updates - newser.com
Oppenheimer Raises Price Target on Ligand Pharmaceuticals to $250 From $190, Keeps Outperform Rating - MarketScreener
Will breakout in Ligand Pharmaceuticals Incorporated lead to full recovery2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock announce a stock splitWeekly Stock Report & Low Drawdown Investment Strategies - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock hit analyst forecastsTrade Exit Summary & Detailed Earnings Play Alerts - newser.com
Can Ligand Pharmaceuticals Incorporated stock sustain market leadership2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Is Ligand Pharmaceuticals Incorporated (LGDN) stock attractive post correctionJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Short interest data insights for Ligand Pharmaceuticals Incorporated2025 Technical Patterns & Long-Term Growth Portfolio Plans - newser.com
What catalysts could drive Ligand Pharmaceuticals Incorporated stock higher2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com
What institutional flow reveals about Ligand Pharmaceuticals IncorporatedWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
Is Ligand Pharmaceuticals Incorporated reversing from oversold territoryJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Analyzing drawdowns of Ligand Pharmaceuticals Incorporated with statistical toolsPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com
What moving averages say about Ligand Pharmaceuticals Incorporated2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
How to use Fibonacci retracement on Ligand Pharmaceuticals IncorporatedWeekly Trend Summary & Advanced Swing Trade Entry Alerts - newser.com
Published on: 2025-11-02 23:44:20 - newser.com
Does Ligand Pharmaceuticals Incorporated show high probability of reboundWeekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com
How Ligand Pharmaceuticals Incorporated (LGDN) stock compares with market leaders2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Technical signs of recovery in Ligand Pharmaceuticals Incorporated2025 Trade Ideas & Fast Gain Stock Tips - newser.com
Is Ligand Pharmaceuticals Incorporated forming a reversal patternJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Ligand Faces Pivotal Week with Earnings and Investor Meetings () - aktiencheck.de
Ligand to Participate in November Investor Conferences - The Manila Times
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):